Interferon-beta for multiple sclerosis: Long-term benefits?

Suppr

超能文献

作者信息

Rudick Richard A, Cutter Gary

出版信息

Ann Neurol. 2007 Apr;61(4):283-5. doi: 10.1002/ana.21119.

DOI:10.1002/ana.21119

PMID:17444503

Abstract

摘要

相似文献

Interferon-beta for multiple sclerosis: Long-term benefits?

Ann Neurol. 2007 Apr;61(4):283-5. doi: 10.1002/ana.21119.

Interferon-beta in multiple sclerosis. Can we control its costs?

Pharmacoeconomics. 1997 Oct;12(4):499-501. doi: 10.2165/00019053-199712040-00007.

Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.

Eur Neurol. 2011;65(3):132-7. doi: 10.1159/000323982. Epub 2011 Feb 12.

Interferon after 10 years in patients with multiple sclerosis.

Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. doi: 10.1007/s10072-006-0697-5.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

Interferon beta in multiple sclerosis: how much BENEFIT?

Lancet. 2007 Aug 4;370(9585):363-4. doi: 10.1016/S0140-6736(07)61170-2.

The gap between effect of drugs and effectiveness of treatments.

J Neurol Sci. 2007 Aug 15;259(1-2):128-32. doi: 10.1016/j.jns.2006.10.024. Epub 2007 Mar 23.

Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.

Neuropediatrics. 2006 Aug;37(4):257-60. doi: 10.1055/s-2006-924723.

Will public health survive QALYs?

Can J Clin Pharmacol. 2002 Spring;9(1):5-6.

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.

Acta Neurol Scand. 2010 Mar;121(3):154-60. doi: 10.1111/j.1600-0404.2009.01285.x. Epub 2010 Jan 6.

引用本文的文献

Interferons at age 50: past, current and future impact on biomedicine.

Nat Rev Drug Discov. 2007 Dec;6(12):975-90. doi: 10.1038/nrd2422.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Interferon-beta for multiple sclerosis: Long-term benefits?

Ann Neurol. 2007 Apr;61(4):283-5. doi: 10.1002/ana.21119.

Interferon-beta in multiple sclerosis. Can we control its costs?

Pharmacoeconomics. 1997 Oct;12(4):499-501. doi: 10.2165/00019053-199712040-00007.

Apolipoprotein alleles and the response to interferon-β-1b in multiple sclerosis.

Eur Neurol. 2011;65(3):132-7. doi: 10.1159/000323982. Epub 2011 Feb 12.

Interferon after 10 years in patients with multiple sclerosis.

Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. doi: 10.1007/s10072-006-0697-5.

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

J Neurol Sci. 2009 Nov 15;286(1-2):109-13. doi: 10.1016/j.jns.2009.06.036. Epub 2009 Jul 16.

Interferon beta in multiple sclerosis: how much BENEFIT?

Lancet. 2007 Aug 4;370(9585):363-4. doi: 10.1016/S0140-6736(07)61170-2.

The gap between effect of drugs and effectiveness of treatments.

J Neurol Sci. 2007 Aug 15;259(1-2):128-32. doi: 10.1016/j.jns.2006.10.024. Epub 2007 Mar 23.

Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.

Neuropediatrics. 2006 Aug;37(4):257-60. doi: 10.1055/s-2006-924723.

Will public health survive QALYs?

Can J Clin Pharmacol. 2002 Spring;9(1):5-6.

Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.

Acta Neurol Scand. 2010 Mar;121(3):154-60. doi: 10.1111/j.1600-0404.2009.01285.x. Epub 2010 Jan 6.

引用本文的文献

Interferons at age 50: past, current and future impact on biomedicine.

Nat Rev Drug Discov. 2007 Dec;6(12):975-90. doi: 10.1038/nrd2422.